UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 28, 2011

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other Jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 733-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the obligation of the registrant under any of the

following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07

Submission of Matters to a Vote of Security Holders

(a) Pfizer’s Annual Meeting of Shareholders was held on April 28, 2011.

(b) Shareholders voted on the matters set forth below.

1. The nominees for election to the Board of Directors were elected, each for a one-year term, based upon the following votes:

Nominee

Votes For

Votes Against

Abstentions

Broker Non-Votes

Dennis A. Ausiello

5,479,523,804

63,025,888

22,031,093

1,029,664,119

Michael S. Brown

5,451,874,773

90,844,187

21,869,298

1,029,664,119

M. Anthony Burns

5,443,824,812

97,791,397

22,971,788

1,029,664,119

W. Don Cornwell

5,170,584,487

364,270,650

29,733,058

1,029,664,119

Frances D. Fergusson

5,214,218,269

328,167,848

22,190,916

1,029,664,119

William H. Gray III

5,385,867,075

156,525,332

22,157,653

1,029,664,119

Constance J. Horner

5,446,823,844

95,839,667

21,890,460

1,029,664,119

James M. Kilts

5,168,196,717

374,127,871

22,229,874

1,029,664,119

George A. Lorch

5,408,148,441

133,916,369

22,488,657

1,029,664,119

John P. Mascotte

5,478,842,805

63,657,172

22,087,732

1,029,664,119

Suzanne Nora Johnson

5,208,605,967

333,835,141

22,109,895

1,029,664,119

Ian C. Read

5,470,406,623

71,686,601

22,406,881

1,029,664,119

Stephen W. Sanger

5,478,015,822

63,584,358

22,950,583

1,029,664,119

2. The proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for 2011 was approved based upon the following votes:

Votes for approval

6,502,916,982

Votes against

64,467,907

Abstentions

26,867,070

Broker Non-Votes

N/A

3. The proposal to approve, on an advisory basis, executive compensation was approved based upon the following votes:

Votes for approval

3,082,645,956

Votes against

2,422,993,133

Abstentions

58,948,621

Broker-Non Votes

1,029,664,119

4.

The proposal on the frequency of future advisory votes on executive compensation received the following votes:

For 3 Years

703,041,341

For 2 Years

1,103,545,026

For 1 Year

3,727,445,064

Abstentions

30,525,614

Broker-Non Votes

1,029,664,119

See Item 5.07(d) below.

5. The shareholder proposal regarding publication of political contributions was not approved based upon the following votes:

Votes for approval

219,466,804

Votes against

4,516,266,497

Abstentions

828,838,153

Broker non-votes

1,029,664,119

6.

The shareholder proposal regarding public policy initiatives was not approved based upon the following votes:

Votes for approval

179,765,706

Votes against

4,578,844,725

Abstentions

805,929,786

Broker non-votes

1,029,664,119

7.

The shareholder proposal regarding pharmaceutical price restraints was not approved based upon the following votes:

Votes for approval

124,165,830

Votes against

4,487,013,964

Abstentions

953,366,804

Broker non-votes

1,029,664,119

8.

The shareholder proposal regarding action by written consent was not approved based upon the following votes:

Votes for approval

2,632,851,163

Votes against

2,878,790,745

Abstentions

52,890,306

Broker non-votes

1,029,664,119

9.

The shareholder proposal regarding special shareholder meetings was not approved based upon the following votes:

Votes for approval

2,290,530,503

Votes against

3,235,353,452

Abstentions

38,653,115

Broker non-votes

1,029,664,119

10.

The shareholder proposal regarding animal research was not approved based upon the following votes:

Votes for approval

197,481,788

Votes against

4,208,648,937

Abstentions

1,158,419,810

Broker non-votes

1,029,664,119

(c) Not applicable.

(d) Based upon the results set forth in item (b) (4) above, the Board of Directors has determined that advisory votes on executive compensation will be submitted to shareholders on an annual basis.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Matthew Lepore

Matthew Lepore

Title: Vice President & Corporate Secretary, Chief Counsel - Corporate Governance

Dated: May 3, 2011